MYOD1 and neoplasm: Experimental evidence suggests that the effectiveness of low-dose decitabine in malignancies stems from its ability to demethylate silenced tumor-suppressor genes related to leukemic malignancies and other myeloid disorders [49] such as p15INK4b, E-cadherin and MYOD1 [50,51].